BCR and B-cell chronic lymphocytic leukemia: The primary mechanism of action of these drugs is inhibition of BCR-induced proliferation and survival signals [174,175,176,177], although inhibition of other BCR-regulated processes has also been shown to contribute to the activity of these drugs, particularly in CLL.